Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma
| Autor: | Stefan von Delius, Stefan Wagenpfeil, Roland M. Schmid, Muhammed Ali Ayvaz, C. Lersch, Florian Eckel |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Pancreatic disease medicine.drug_class medicine.medical_treatment Low molecular weight heparin Antineoplastic Agents Adenocarcinoma Gastroenterology Internal medicine medicine Humans Neoplasm Metastasis Survival analysis Aged Retrospective Studies Aged 80 and over Chemotherapy business.industry Hazard ratio Retrospective cohort study Hematology Heparin Low-Molecular-Weight Middle Aged Metastatic Pancreatic Adenocarcinoma medicine.disease Survival Analysis Surgery Pancreatic Neoplasms Drug Evaluation Female business |
| Zdroj: | Thrombosis and Haemostasis. 98:434-439 |
| ISSN: | 2567-689X 0340-6245 |
| Popis: | SummaryThis retrospective analysis aimed to identify whether low-molecular- weight heparins (LMWH) might improve survival in patients receiving chemotherapeutic treatment for advanced pancreatic adenocarcinoma.Two hundred forty-three patients who had received chemotherapy for advanced pancreatic adenocarcinoma were identified from a prospectively maintained database. Of these, 30 patients had to be excluded from analysis due to insufficient documentation. Of the remaining 213 patients 94 patients had been treated with LMWH, whereas 119 patients served as controls. Outcome was assessed in relation to overall survival, which was calculated from the date of initiation of chemotherapy to the date of death.There was no significant difference (hazard ratio, 0.8; 95% confidence interval (CI), 0.6 to 1.1; P=0,2) between the two groups in terms of overall survival. The median survival was 7.1 months (95% CI,5.8–8.4 months) in the LMWH group and 5.9 months (95% CI, 5.1–6.7 months) in the non-LMWH group. A positive effect of LMWH was seen in patients with metastatic disease (hazard ratio for LMWH vs. non-LMWH, 0,6; 95% CI, 0,4 to 0,8; P=0,006) in contrast to those without metastatic disease (hazard ratio for LMWH vs. non-LMWH, 1; 95% CI, 0.6 to 1.7; P=0,96).The median survival of patients with metastatic disease was 6,6 months (95% CI, 5–8,2 months) and 3.8 months (95% CI, 2.5–5.1 months) for the LMWH group and the non-LMWH group, respectively. In conclusion, we found for metastatic pancreatic adenocarcinoma a survival advantage for patients receiving LMWH. Nevertheless, our observations need confirmation by prospective randomized studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|